[go: up one dir, main page]

TR200101182T2 - Delivery of dry powder active substance to the lung. - Google Patents

Delivery of dry powder active substance to the lung.

Info

Publication number
TR200101182T2
TR200101182T2 TR2001/01182T TR200101182T TR200101182T2 TR 200101182 T2 TR200101182 T2 TR 200101182T2 TR 2001/01182 T TR2001/01182 T TR 2001/01182T TR 200101182 T TR200101182 T TR 200101182T TR 200101182 T2 TR200101182 T2 TR 200101182T2
Authority
TR
Turkey
Prior art keywords
active substance
lung
dry powder
delivery
powder active
Prior art date
Application number
TR2001/01182T
Other languages
Turkish (tr)
Inventor
Clark Andrew
Kuo Mei-Chang
Lalor Cecily
John Aldous Barry
Original Assignee
Inhale Therapeutic Systems, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhale Therapeutic Systems, Inc. filed Critical Inhale Therapeutic Systems, Inc.
Publication of TR200101182T2 publication Critical patent/TR200101182T2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

Bu bulus partikülat terkipleriyle ve bir aktif maddenin, bir hastanin akcigerine iletim yöntemleriyle ilgilidir. Aktif madde kuru toz halinde olup, özellikle simüle akciger kosullari altinda, (i) düsük nem emme, ve (ii) hidroskopik büyümeye direnç gösterme özellikleri vardir.This invention relates to particulate preparations and methods of delivering an active substance to the lung of a patient. The active substance is in dry powder form, especially under simulated lung conditions, it has (i) low moisture absorption and (ii) resistance to hydroscopic growth.

TR2001/01182T 1998-09-14 1999-09-13 Delivery of dry powder active substance to the lung. TR200101182T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10016398P 1998-09-14 1998-09-14

Publications (1)

Publication Number Publication Date
TR200101182T2 true TR200101182T2 (en) 2001-09-21

Family

ID=22278404

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/01182T TR200101182T2 (en) 1998-09-14 1999-09-13 Delivery of dry powder active substance to the lung.

Country Status (44)

Country Link
EP (1) EP1117442A1 (en)
JP (1) JP2002524535A (en)
KR (1) KR20010075063A (en)
CN (1) CN1317977A (en)
AP (1) AP1374A (en)
AR (1) AR022090A1 (en)
AU (1) AU753014B2 (en)
BG (1) BG105430A (en)
BR (1) BR9913722A (en)
CA (1) CA2343920A1 (en)
CO (1) CO5130023A1 (en)
CZ (1) CZ2001829A3 (en)
DZ (1) DZ2892A1 (en)
EA (1) EA003476B1 (en)
EE (1) EE200100151A (en)
GE (1) GEP20043257B (en)
GT (1) GT199900156A (en)
HK (1) HK1042231A1 (en)
HN (1) HN1999000159A (en)
HR (1) HRP20010189A2 (en)
HU (1) HUP0103837A3 (en)
ID (1) ID28845A (en)
IL (2) IL141562A0 (en)
IS (1) IS5878A (en)
LT (1) LT4897B (en)
LV (1) LV12658B (en)
MA (1) MA25590A1 (en)
MY (1) MY129282A (en)
NO (1) NO20011251L (en)
NZ (1) NZ510168A (en)
OA (1) OA11781A (en)
PA (1) PA8481901A1 (en)
PE (1) PE20001061A1 (en)
PL (1) PL195574B1 (en)
SA (1) SA99200718B1 (en)
SK (1) SK3442001A3 (en)
TN (1) TNSN99173A1 (en)
TR (1) TR200101182T2 (en)
TW (1) TWI226248B (en)
UA (1) UA76085C2 (en)
UY (1) UY25711A1 (en)
WO (1) WO2000015262A1 (en)
YU (1) YU24201A (en)
ZA (1) ZA200101995B (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6956021B1 (en) 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
WO2000075281A2 (en) 1999-06-09 2000-12-14 University Technology Corporation Supercritical fluid-assisted nebulization and bubble drying
US6475468B2 (en) * 2001-02-15 2002-11-05 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
JP2005503425A (en) * 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション Delivery of drug ester by the prescribed inhalation route
EG24184A (en) * 2001-06-15 2008-10-08 Otsuka Pharma Co Ltd Dry powder inhalation system for transpulmonary
US7182961B2 (en) 2001-11-20 2007-02-27 Advanced Inhalation Research, Inc. Particulate compositions for pulmonary delivery
AU2003215396B2 (en) 2002-02-25 2010-04-08 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
JP2006513139A (en) * 2002-07-03 2006-04-20 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド Central airway administration for systemic delivery of therapeutic agents
WO2004060352A1 (en) * 2002-12-19 2004-07-22 Pharmacia Corporation Non-hygroscopic formulation comprising a hydroscopic drug
DE10338403A1 (en) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder formulation containing the CGRP antagonist 1- [N 2 - [3,5-dibromo-N - [[4- (3,4-dihydro-2 (1 H) -oxoquinazolin-3-yl] -1-piperidinyl] carbonyl] -D-tyrosyl] -L-lysyl] -4- (4-pyrindinyl) piperazine, process for its preparation and its use as inhalant
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
AU2005237523A1 (en) * 2004-04-23 2005-11-10 Cydex Pharmaceuticals, Inc. DPI formulation containing sulfoalkyl ether cyclodextrin
UA95903C2 (en) 2005-02-24 2011-09-26 Дифьюжен Фармасьютикалз Ллк Trans carotenoids, their synthesis, formulation and uses
KR20070110418A (en) * 2005-03-09 2007-11-16 오노 야꾸힝 고교 가부시키가이샤 Particles and Formulations Containing the Particles
MX383536B (en) 2005-10-26 2025-03-14 Cydex Pharmaceuticals Inc SULFOALKYL ETHER-CYCLODEXTRIN COMPOSITIONS AND METHODS OF PREPARING SAME.
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
WO2008021451A2 (en) * 2006-08-14 2008-02-21 Aktiv-Dry Llc Human-powered dry powder inhaler and dry powder inhaler compositions
CN101541311B (en) * 2006-10-25 2013-01-23 大日本住友制药株式会社 Granular preparation prevented from caking
EP1925295A1 (en) * 2006-11-22 2008-05-28 Boehringer Ingelheim Pharma GmbH & Co. KG Stable powder formulation containing a new antichinolinergic agent
KR101570131B1 (en) 2007-04-13 2015-11-18 디퓨젼 파마슈티컬즈 엘엘씨 Use of bipolar transcarotenoids for the treatment and prevention of peripheral vascular disease
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
JP2011502125A (en) 2007-10-31 2011-01-20 ディフュージョン・ファーマシューティカルズ・エルエルシー A new class of treatments that promote small molecule diffusion
PL2432502T3 (en) 2009-05-20 2018-05-30 Aeras Stable, spray dried, immunogenic, viral compositions
CN108464976A (en) 2009-06-22 2018-08-31 扩散药品有限公司 Diffusion promotes compound and its independent or application together with Thrombolytic Drugs
WO2011152869A1 (en) 2010-06-02 2011-12-08 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
CA2866230C (en) 2012-05-03 2020-08-18 Janssen R&D Ireland Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections
WO2014074797A1 (en) * 2012-11-09 2014-05-15 Civitas Therapeutics, Inc. Ultra low density pulmonary powders
US20180043585A9 (en) * 2013-09-20 2018-02-15 Virginia Commonwealth University Delivery of particles using hygroscopic excipients
DK3212212T3 (en) 2014-10-31 2020-12-21 Univ Monash POWDER FORMULATION
CN115089569A (en) 2016-03-24 2022-09-23 扩散药品有限公司 Use of bipolar trans carotenoids in conjunction with chemotherapy and radiation therapy for the treatment of cancer
US20220378727A1 (en) * 2021-05-14 2022-12-01 The University Of Hong Kong Dry powder formulations of tamibarotene for pulmonary and intranasal delivery

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155573A (en) * 1958-05-06 1964-11-03 Benger Lab Ltd Inhalant composition and method of making same
CA2115065C (en) * 1992-06-12 2000-10-03 Kiyoyuki Sakon Ultrafine particle powder for inhalation and method for production thereof
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
PT954282E (en) * 1997-01-16 2005-06-30 Massachusetts Inst Technology PREPARATION OF PARTICLES FOR INHALATION
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant

Also Published As

Publication number Publication date
EA003476B1 (en) 2003-06-26
CO5130023A1 (en) 2002-02-27
SA99200718B1 (en) 2006-11-04
IS5878A (en) 2001-03-05
EP1117442A1 (en) 2001-07-25
SK3442001A3 (en) 2001-11-06
GEP20043257B (en) 2004-06-25
UY25711A1 (en) 1999-11-17
LT4897B (en) 2002-02-25
AU6039799A (en) 2000-04-03
DZ2892A1 (en) 2003-12-15
HUP0103837A2 (en) 2002-05-29
ID28845A (en) 2001-07-05
HRP20010189A2 (en) 2005-04-30
HUP0103837A3 (en) 2002-11-28
AU753014B2 (en) 2002-10-03
CN1317977A (en) 2001-10-17
MA25590A1 (en) 2002-12-31
OA11781A (en) 2005-07-26
TWI226248B (en) 2005-01-11
KR20010075063A (en) 2001-08-09
NO20011251D0 (en) 2001-03-13
LT2001021A (en) 2001-11-26
PL346768A1 (en) 2002-02-25
LV12658B (en) 2001-09-20
CA2343920A1 (en) 2000-03-23
MY129282A (en) 2007-03-30
IL141562A (en) 2007-07-24
HN1999000159A (en) 1999-11-11
EA200100300A1 (en) 2001-10-22
PA8481901A1 (en) 2002-04-25
GT199900156A (en) 2001-03-07
YU24201A (en) 2003-08-29
EE200100151A (en) 2002-06-17
ZA200101995B (en) 2002-03-11
AR022090A1 (en) 2002-09-04
NO20011251L (en) 2001-04-17
AP2001002093A0 (en) 2001-03-31
PE20001061A1 (en) 2000-10-08
IL141562A0 (en) 2002-03-10
AP1374A (en) 2005-02-28
BR9913722A (en) 2001-05-29
UA76085C2 (en) 2006-07-17
HK1042231A1 (en) 2002-08-09
JP2002524535A (en) 2002-08-06
PL195574B1 (en) 2007-10-31
WO2000015262A1 (en) 2000-03-23
LV12658A (en) 2001-05-20
NZ510168A (en) 2003-09-26
BG105430A (en) 2001-12-29
CZ2001829A3 (en) 2001-09-12
TNSN99173A1 (en) 2005-11-10

Similar Documents

Publication Publication Date Title
TR200101182T2 (en) Delivery of dry powder active substance to the lung.
EA200301275A1 (en) CAPSULES FOR INHALATION
TR200100922T2 (en) Application of active substances through the lungs.
FI935304A7 (en) Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
IT1232827B (en) BIOLOGICALLY ACTIVE PROTEINS, FORMULATIONS CONTAINING THEM AND METHOD TO PREPARE AND APPLY THEM
NO921791L (en) NICOTINE-CONTAINING, STIMULATIVE DEVICE
SE8307026L (en) WATER-SOLUBLE, AMINATED BETA-1,3-BUNDLE D-GLUCAN AND COMPOSITION CONTAINING ITS SAME
FI952119L (en) Stable freeze-dried formulation containing protein and test kit
AR028315A2 (en) 1-ARILPIRAZOLCARBOXALDEHYD HYDRAZONE COMPOUNDS OF PESTS OF SYSTEMIC ACTIVITY IN THE REPRESSION OF PESTS OF ARTROPODES, HELMINTOS, NEMATODOSS AND PROTOZO; PROCEDURES TO PREPARE THEM AND PESTICIDE COMPOSITIONS CONTAINING IT, AND METHODS OF APPLICATION OF SUCH COMPOUNDS FOR THE REPRESENTATIVE
SE8009068L (en) PARTICLES OF LIPOID SOLUBLE SUBSTANCES, MIXTURES INCLUDING SUCH PARTICLES AND THESE ADSORBED BIOLOGICALLY ACTIVE SUBSTANCES LIKE ALSO SEEN FOR PREPARATION OF SUCH MIXTURES
EE05620B1 (en) Omeprazole microgranules, process for their preparation and pharmaceutical preparations
NO865079D0 (en) STABILIZED HUMAN TISSUE PLAMINOGEN ACTIVATOR PREPARATIONS.
ATE210975T1 (en) TOPICAL PREPARATIONS CONTAINING N-ACETYL-L-CYSTEIN
TR199902730T2 (en) Pharmaceutical antiviral composition containing glycyrrhizic acid and at least one protein imparted antiviral activity.
ATE201823T1 (en) TOPICAL PHARMACEUTICAL COMPOSITIONS CONTAINING HEPARIN
FI840428A7 (en) Biologically active ketone derivative, its preparation and use.
IT8520059A0 (en) PROCEDURE AND SYSTEM FOR THE REDUCTION OF THE HARMFUL SUBSTANCE CONTENT OF COMBUSTED GAS.
FI861526A7 (en) Nitrofuran derivatives, their preparation and application in therapy.
IT8919975A0 (en) SYNERGISTICALLY ACTIVE VETERINARY COMPOSITIONS AND PROCEDURE FOR THEIR PREPARATION.
BG46592A3 (en) FUNGICIDE COMPOSITION AND METHOD FOR COMBATING FUNGI
UA39899C2 (en) Preparation Method DRY POWDER Loose ATSYFLUORFENU OR agronomic suitable salts (option), prepared in this way loose DRY POWDER (option) AND PVA package containing CUHYY Loose Powder (option)
NO20003888L (en) Anti-enzyme preparations comprising ethylenediaminea succinic acid
BG40951A3 (en) Herbicide means
NL188891C (en) PHARMACEUTICAL PREPARATION WITH BLOOD PRESSURE-REDUCING EFFECT CONTAINING CO-DERGOCRINE AND ANOTHER ACTIVE MATERIAL.
ATE26109T1 (en) ACETYLCYSTEINE SALTS, THEIR PREPARATION AND USE.